
APOLIPOPROTEIN(a) POLYMORPHISMS IN A HEALTHY MACEDONIAN POPULATION Tosheska K*, Labudovic D, Alabakovska S, Todorova B *Corresponding Author: Katerina Tosheska K, MD, MSc., Department of Medical and Experimental Biochemistry, Faculty of Medicine, 50 Divizija 6, 1000 Skopje, Republic of Macedonia; Tel: +389-2-3217-303; Fax: +389-2-3230-431; E-mail: tosheskatrajkovska@yahoo.com
page: 49
|
RESULTS
Five apo(a) isoforms (B, S1, S3, S4 and >S4) were resolvable by the SDS-PAGE system followed by immunoblotting with a sheep polyclonal anti-human apo(a) antibody. In each plasma, one of these five bands was generally present, either alone (single-banded phenotype) or in combination with another band (double-banded phenotype). The phenotype was defined as “null” when there were no detectable apo(a) bands.
The frequency of apo(a) phenotypes in the test subjects is shown in Table 1. One hundred and seven (59.44%) had single-banded phenotypes and 64 (35.56%) had double-banded phenotypes. Nine individuals (5%) had the “null” phenotype. There was no significant difference in the apo(a) isoform frequency distribution between gender groups (P2 = 0.514, p = 0.77).
All five of the possible single-banded phenotypes and eight of the 12 possible double-banded phenotypes were detected. The frequencies of single-banded and double-banded phenotypes are given in Table 2. Among the single-banded phenotypes, S4 was the most frequent (49.14%) and S1 and B were comparatively rare (1.72%). The S4/S3 phenotype was the most frequent (43.75%) among the double-banded phenotypes.
Based upon the hypothesis that the apo(a) polymorphism is controlled by different alleles at a single locus, the frequencies of the six alleles were: LpB = 0.022, LpS1 = 0.028, LpS3 = 0.201, LpS4 = 0.397, Lp>S4 =0.110, and LpO = 242. Comparison of the observed phenotype frequencies with those expected from the genetic hypothesis, and assuming that the Hardy-Weinberg equilibrium showed no significant difference [P2 =17.21, degrees of freedom (df) = 15, p <0.3067) (Table 2).
As shown in Figure 1, the distribution of Lp(a) concentration is highly skewed towards lower concentrations with most of the subjects, 164 (91.1%) having an Lp(a) level beneath the cut-off point of 30 mg/dL. The plasma level of Lp(a) in males and females is presented in Table 3. There was no significant difference in plasma Lp(a) levels between the sexes (two-sample unpaired Student’s t-test, p = 0.4246). The Mr of apo(a) isoforms and Lp(a) concentrations are presented in Table 4. We confirmed that low Mr isoforms (B, S1) are associated with elevated Lp(a) concentrations, whereas the high Mr isoforms (S4 and S3) are associated with lower Lp(a) levels. We found a significant inverse correlation [Pearson’s correlation coefficient (r) = –0.3477, p <0.001) between the Mr of apo(a) isoforms and plasma levels of Lp(a) (Fig. 2).
Table 1. Frequency of apo(a) phenotypes in 180 Macedonian blood donors
Isoform |
Males |
Females |
Total |
|
n |
% |
n |
% |
n |
% |
Single |
58 |
61.10 |
49 |
56.98 |
107 |
59.44 |
Double |
32 |
|
Table 2. Frequency of observed and expected phenotypes in 180 Macedonian blood donors
Isoform |
Observed Apo(a) Isoform |
Expected Apo(a) Isoform |
Single |
n |
% |
n |
% |
>S4 |
14 |
12.07 |
11,767 |
10.27 |
S4 |
57 |
49.14 |
62,804 |
54.81 |
S3 |
32 |
27.59 |
24,810 |
21.65 |
S1 |
2 |
1.72 |
2591 |
2.26 |
B |
2 |
1.72 |
2,050 |
1.79 |
Null |
9 |
7.76 |
10,565 |
9.22 |
Total |
116 |
100.00 |
114,597 |
100.00 |
Double |
n |
% |
n |
% |
>S4/S4 |
22 |
34.38 |
15,683 |
23.92 |
>S4/S3 |
1 |
1.56 |
7,959 |
12.14 |
>S4/S1 |
0 |
0.00 |
1,112 |
1.70 |
S4/S3 |
28 |
43.75 |
28,673 |
43.75 |
S4/S1 |
6 |
9.38 |
4,005 |
6.11 |
>S4/B |
0 |
0.00 |
889 |
1.36 |
S4/B |
4 |
6.25 |
3,204 |
4.89 |
S3/S1 |
1 |
1.56 |
2,032 |
3.10 |
S3/B |
1 |
1.56 |
1,626 |
2.48 |
S1/B |
1 |
1.56 |
352 |
0.54 |
Total |
64 |
100.00 |
65,535 |
100.00 |

Figure 1. Frequency distribution of Lp(a) concentration

Figure 2. Correlation between Mr of apo(a) isoforms and Lp(a) concentration.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|